Phase II evaluation of didemnin B in hormonally refractory metastatic prostate cancer - A southwest oncology group study

Stephen K. Williamson, Michael K. Wolf, Mario A. Eisenberger, Mark O'Rourke, William Brannon, E. David Crawford

Research output: Contribution to journalArticle

Abstract

Didemnin B, a dipsipeptide isolated from the Caribbean tunicate Trididemnum with antitumor and antiviral activity was evaluated in a phase II trial in the treatment of metastatic, hormonally refractory adenocarcinoma of the prostate. Thirteen patients were treated with didemnin B at 3.5 mg/m2 and 20 patients were treated at 6.3 mg/m2 intravenously every 28 days. Response was assessed every 8 weeks. Of 32 evaluable patients there was one partial response for an overall response rate of 3% (95% confidence interval of 0.1-16%). The most common toxicities were nausea, vomiting, and diarrhea. Serious cardiac and pulmonary toxicities were also noted. This drug does not appear to warrant further evaluation in this disease as a single agent.

Original languageEnglish (US)
Pages (from-to)167-170
Number of pages4
JournalInvestigational New Drugs
Volume13
Issue number2
DOIs
StatePublished - Jun 1995

Keywords

  • didemnin B
  • phase II
  • prostate cancer

ASJC Scopus subject areas

  • Oncology
  • Pharmacology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Phase II evaluation of didemnin B in hormonally refractory metastatic prostate cancer - A southwest oncology group study'. Together they form a unique fingerprint.

  • Cite this